Shots:
- Spotlight Medical has received CE marking under the EU IVDR for myStage Dx, an AI-enabled prognostic test designed to support risk stratification in patients with ER+/HER2- early breast cancer
- Test analyzes digitized H&E-stained FFPE pathology slides alongside routine clinicopathological variables to generate a binary prognostic classification of Low Risk or Not Low Risk
- In studies across the CANTO & UNIRAD cohorts, myStage Dx identified 19.4% of clinically high-risk pts as Low Risk, with 95.4% remaining free of distant recurrence & breast cancer-related death at 9yrs. vs 76.8% in the Not Low Risk group; data published in the JCO
Ref: Businesswire | Image: Spotlight Medical | Press Release
Related News: FiberSense Receives CE Mark for its Continuous Glucose Monitoring (CGM) System
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
